SUPERSTRING CAPITAL MANAGEMENT LP
Q3 2024 Form 13-F
NEW YORK, DELAWARE
CIK 0001931118
· CRD 305743
· SEC-registered investment adviser
$114.2M Reported Value Total
SUPERSTRING CAPITAL MANAGEMENT LP reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $218,300,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $315.7M gross asset value
Hedge Fund: $281.3M · Private Equity Fund: $34.4M
Source: Form ADV filed 2026-03-30
Reported value
$114.2M
Quarter over quarter
+4.9%
Holdings
27
Top-10 concentration
76.1%
Key People
Form ADV owners & control persons
Guo Ting
MANAGING PARTNER
Mark Peter Doherty
CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2024 13F record
Q3 2024 13F filing summary
| Period of report | September 30, 2024 |
|---|---|
| Filed | November 14, 2024 |
| Form | 13F-HR |
| Reported value | $114.2M |
| Positions | 27 |
| Change in reported value | +44.0% |
| New positions | 8 |
| Exited positions | 20 |
| Position turnover | 59.6% |
| Top-10 concentration | 76.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
32 | $158.4M |
|
Q1 2026 13F
Filed May 14, 2026
|
35 | $140.0M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
45 | $186.8M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
35 | $101.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
35 | $84.5M |
|
Q1 2025 13F
Filed May 15, 2025
|
33 | $84.0M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
38 | $115.5M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
27 | $114.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
39 | $79.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
37 | $151.2M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
30 | $140.1M |
Top 20 holdings · Q3 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ZLAB ZAI LAB LTD | $15.1M | 13.25% |
| 2 | CYTK CYTOKINETICS INC | $11.4M | 9.97% |
| 3 | TERN TERNS PHARMACEUTICALS INC | $11.2M | 9.84% |
| 4 | GPCR STRUCTURE THERAPEUTICS INC | $10.0M | 8.72% |
| 5 | ORIC ORIC PHARMACEUTICALS INC | $9.7M | 8.52% |
| 6 | TIL INSTIL BIO INC | $7.2M | 6.34% |
| 7 | NVCR NOVOCURE LTD | $6.1M | 5.37% |
| 8 | BBIO BRIDGEBIO PHARMA INC | $5.8M | 5.05% |
| 9 | FATE FATE THERAPEUTICS INC | $5.1M | 4.49% |
| 10 | CAPR CAPRICOR THERAPEUTICS INC | $5.1M | 4.49% |
| 11 | TNGX TANGO THERAPEUTICS INC | $4.6M | 4.04% |
| 12 | ETNB 89BIO INC | $4.4M | 3.86% |
| 13 | NKTX NKARTA INC | $3.3M | 2.93% |
| 14 | LEGN LEGEND BIOTECH CORP | $2.9M | 2.58% |
| 15 | ZLAB C ZAI LAB LTD | $2.4M | 2.11% |
| 16 | ZBIO ZENAS BIOPHARMA INC | $1.9M | 1.65% |
| 17 | ALLO ALLOGENE THERAPEUTICS INC | $1.3M | 1.17% |
| 18 | SYRE SPYRE THERAPEUTICS INC | $1.1M | 0.96% |
| 19 | SVRA SAVARA INC | $848.0K | 0.74% |
| 20 | BMEA BIOMEA FUSION INC | $843.9K | 0.74% |
Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.